No Data
No Data
Mirum Pharmaceuticals To Showcase LIVMARLI Data From Its ALGS And PFIC Programs At The NASPGHAN Annual Meeting
Leerink Partners Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Raises Target Price to $49
Mirum Pharmaceuticals Price Target Raised to $49 From $47 at Leerink
Catalyst Watch: Netflix Earnings, Lenovo Tech Event, Paris Motor Show, and Eyes on Oil
H.C. Wainwright Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Maintains Target Price $66
Mirum's Liver Disease Drug Candidate Gets FDA Breakthrough Designation